US Breast Cancer Drug Antibodies Immunotherapy Therapeutics Market Offers USD 20 Billion Opportunity by 2026
US Breast Cancer Market will Be Driven By New Product Launches & Increasing Number of Clinical Trials Of New Novel Therapeutics Says Kuick Research
DELHI, India, Jan. 20, 2021 (GLOBE NEWSWIRE) -- *"US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026" *Report Highlights:· US Breast Cancer Drug Market: > USD 20 Billion Opportunity by 2026
· US Breast Cancer clinical Trials: 350 Drugs in Pipeline
· More Than 130 Drugs in Phase II & Higher Phases of Trials
· Detailed Clinical Insight on 350 Drugs In Pipeline & 62 Drugs Available in Market
· Marketed Breast Cancer Drugs Dosage, Patent & Pricing
· Drugs Classification by Class: SERD, EGFR, Mitotic Inhibitors, CDK 4/6, Hormonal, PARP Inhibitors & More
· Insight on Ongoing Research & Collaborations
· 900 Page In-Depth Analysis on Clinical & Commercial Indicators
Download Report:
*https://www.kuickresearch.com/report-us-usa-breast-cancer-drug-therapy-therapeutics-market-sales-size-share--demand-forecast--metastatic-breast-cancer-marker-vaccine-immunotherapy-antibody-antibodies-egfr-pdl1--peptides-biosimilars-generics--oral-serd-radiotherapy--inhibitors *
US breast cancer market has experienced advancements in the sector which have significantly improved the patient outcomes. The US breast cancer market when compared with the global breast cancer therapeutics market is a cutting-edge high tech firm which is packed with tons of healthcare opportunities. On the next generation of the healthcare facilities, US breast cancer therapeutics market is on the edge of providing the patients with the medical options that are specifically personalized depending on the hallmarks of the breast cancer. Our analysis for the US breast cancer market indicated that the overall healthcare opportunities and novel drug launches in the country can go higher than it has observed in the past few years. Based on every pharmaceutical technology and tools available in the country for the researchers, the extensive investment in the breast cancer research and development and further arrival of novel potential therapies are believed to accelerate the growth rate.
In the past few years, breast cancer market in the US has been declared as a major focused area for the major key players in the market, with an estimated 534 clinical trials in development. In addition to this, the overall commercial setting in the country with respect to the availability of breast cancer drugs is also inclining towards synergistic boosting of the growth parameters and opinion leader market when compared with the other emerging breast cancer markets in the world. In the research and development setting, researchers are oriented towards working against the major hallmarks of the breast cancer cells such as specific potential markers that could help the researchers to come up with specific diagnostic tools and inhibitors.
In short term, the US breast cancer therapeutics market is estimated to continue its large drive in the overall market by working on the settings that have great importance in the fast-end development of the market. The increasing number of major bio-pharmaceutical companies and local drug makers on breast cancer therapeutics market, competition for the access growth rate is also becoming aggressively intense. Same has gradually led to shortened cycle for developing a novel drug and thus causing the emergence of the US market as a world leader.
As per the research conducted for US breast cancer therapeutics market, it is estimated that the country is fledged with the success environment due to several novel drug launches, robust and strong clinical pipeline timeframe, and research and development paradigms focusing on greater emphasis on meeting the needs of the patient population. The overall arrival of the breast cancer therapeutics market in the country has aligned the researchers in the country to transform the entire unstructured breast cancer management services into a well-defined structure. All the major insights available for the market indicates towards an era that is well-designed to tackle the complexities that are generally observed in treating last stage breast cancer. As per the extensive research conducted, it is believed that the driving forces aligned within the market will surpass the complex challenges in small fraction of time, when compared with other breast cancer markets in the world. In addition to this, growing healthcare infrastructure, increasing per capita income, large novel launches of drugs and many more are estimated to fuel the market in the next few years. Excessive penetration of all the defined parameters are estimated to develop more strong and robust landscape for breast cancer drugs in the future years.
*Table of Contents*
*1. US Breast Cancer Drug Market Analysis*1.1 US Breast Cancer Market Overview1.2 Current Market Scenario
*2. Approved Breast Cancer Drugs by Class*2.1 Chemotherapeutic Drugs2.2 Hormonal Therapy2.3 Immunotherapeutic Drugs 2.3.1 Targeted Antibodies (ADC/Monclonal /Trispecific) 2.3.2 Immune Checkpoint Inhibitors2.4 Kinase Inhibitors
*3. New Emerging Therapies in Breast Cancer*3.1 Targeted Endocrine Therapy3.2 Oral Selective Estrogen Receptor Degrader (SERD)3.3 Immunotherapeutics through Cancer Vaccines3.4 Tri-Specific NK Cell Engagers (TriKE)3.5 Adoptive T Cell Therapy
*4. US Breast Cancer Drug: Generic & Biosimilar Landscape*4.1 Current Scenario & Price Differential4.2 Reimbursement Policy
*5. US - Breast Cancer Clinical Trials Overview*5.1 By Drug Class5.2 By Formulation5.3 By Organization5.4 By Patient Segment5.5 By Phase5.6 By Target
*6. US - Breast Cancer Clinical Trials By Company, Indication & Phase*6.1 Research6.2 Preclinical6.3 Clinical6.4 Phase-06.5 Phase-I6.6 Phase-I/II6.7 Phase-II6.8 Phase-II/III6.9 Phase-III6.10 Preregistration6.11 Registered
*7. US - Marketed Breast Cancer Drugs Clinical Insight*
*8. CDK 4/6 Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*8.1 Ribociclib (Kisqali)8.2 Abemaciclib (Verzenio)8.3 Palbociclib (Ibrance)
*9. EGFR Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*9.1 Nertinib (Nerlynx)9.2 Lapatinib (Tykerb)
*10. Mitotic Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*10.1 Ixabepilone (Ixempra)10.2 Eribulin (Halaven)10.3 Paclitaxel-Protein Bound (Abraxane)10.4 Paclitaxel (Taxol)10.5 Docetaxel (Taxotere)
*11. Aromatase Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*11.1 Anastrazole (Arimidex)11.2 Letrozole (Femara)11.3 Exemestane (Aromasin)
*12. Hormonal Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*12.1 Raloxifene (Evista)12.2 Tamoxifen (Soltamax)12.3 Testosterone Cypionate (Depo-Testosterone)12.4 Fluoxymesterone12.5 Fareston (Toremifene)
*13. Antimetabolite Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*13.1 Gemcitabine (Gemzar)13.2 Capecitabine (Xeloda)13.3 Flourouracil13.4 Methotrexate
*14. PARP Inhibitors for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*14.1 Olaparib (Lynparza)14.2 Talazoparib (Telzenna)
*15. Immunotherapy Drugs for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*15.1 Herceptin (Trastuzumab)15.2 Avastin (Bevacizumab)15.3 Perjeta (Pertuzumab)15.4 Kadcyla (Ado-Trastuzumab Emtansine)15.5 Tecentriq (Atizolizumab)15.6 Keytruda (Pembrolizumab)15.7 Enhertu (Fam-Trastuzumab Deruxtecan)15.8 Phesgo (Hyaluronidase / Pertuzumab / Trastuzumab)15.9 Herceptine Hylecta (Hyaluronidase / Trastuzumab)15.10 Trodelvy (Sacituzumab Govitecan)
*16. SERD for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*16.1 Fulvestrant (Faslodex) - Approval & Patent Dispute16.2 Pricing & Dosage Analysis16.3 Sales Analysis
*17. Alkylating Agents for Breast Cancer - US Market Availability, Dosage, Patent & Price Insight*17.1 Cyclophosphamide17.2 Thiotepa
*18. Other Breast Cancer Drugs - US Market Availability, Dosage, Patent & Price Insight*18.1 Tucatinib18.2 Doxorubicin18.3 Everolimus18.4 Alpelisib (Piqray)
*19. US Breast Cancer Market Insights for Ongoing Research Work & Development*19.1 Single Dose Radiotherapy Beneficial Over Other Conventional Breast Cancer Treatment Options19.2 Targeted Therapy to Emerge as Novel & Promising Opportunity for Breast Cancer Treatment19.3 UCLA Researchers Define the Lack of Predictive Biomarkers in Breast Cancer Treatment19.4 Development of Novel Model for Breast Cancer Patients by UCSF Researchers19.5 Artificial Intelligence Applications Aids in the Development of Breast Cancer Treatment19.6 More Promising Survival Rate of the Breast Cancer Patients due to Surgery Applications19.7 Immunotherapy to Converge the Entire US Breast Cancer Market towards its Applications19.8 Estrogen Positive Breast Cancer Patients to Receive Potential Drug Combination for Treatment19.9 TNBC to Receive Special Attention for Novel Therapeutic Treatment Option19.10 Rockefeller University Researchers to Introduce Telomere into Breast Cancer Treatment19.11 Veru Oncology Pharmaceuticals Expansion of Clinical Pipeline for Breast Cancer19.12 MIT Researchers to Revolutionize Breast Cancer Screening Methodologies by Artificial Intelligence Applications19.13 Researchers to Explore More Hidden Parameters for Breast Cancer Tumors19.14 Environmental Factors Exposure Study on Breast Cancer Development19.15 Targeted Therapy to Improve Breast Cancer Treatment in Mice Model
*20. Research & Collaborations Advancing the US Breast Cancer Market at a Splendid Rata*20.1 Celcuity, Massachusetts General Hospital & Puma Biotechnology to Enter into Collaboration for Advancing US Breast Cancer Market20.2 US Based Pharmaceutical Company Pfizer to Collaborate with Japanese Pharmaceuticals to Expand Breast Cancer Market20.3 MacroGenics & EVERSANA to Collaborate for Launch & Commercialization of Margetuximab Drug20.4 New York Based Ibi & Atos Partners to Build Data for Breast Cancer Studies20.5 NCCN & Pfizer to Collaborate for the Development of Metastatic Breast Cancer Market20.6 Alphamab Oncology & Pfizer to Work Together on Ibrance Drug for HER2 Positive Breast Cancer Patients20.7 Pfizer & Zymeworks to collaborate for Evaluating ZW25 Combination Therapy in Breast Cancer Patients20.8 Pfizer & Flatiron Health to Expand Market for Breast Cancer Medicine Development
* 21. US Breast Cancer Market Dynamics*21.1 Market Favorable Parameters21.2 Market Challenges
* 22. US Breast Cancer Market Future Prospects*
* 23. Competitive Landscape*23.1 Agilent Technologies23.2 AstraZeneca23.3 Bayer HealthCare Pharmaceuticals23.4 Bristol-Myers Squibb23.5 Eisai Co Ltd23.6 Eli Lilly23.7 Novartis23.8 Onyx Pharmaceuticals23.9 Orion23.10 Perrigo23.11 Pfizer23.12 Roche
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366